A. Hervieu, C. Rebe, F. Vegran, F. Chalmin, and M. Bruchard, Dacarbazine-Mediated Upregulation of NKG2D Ligands on Tumor Cells Activates NK and CD8 T Cells and Restrains Melanoma Growth, Journal of Investigative Dermatology, vol.133, issue.2, 2012.
DOI : 10.1038/jid.2012.273

URL : https://hal.archives-ouvertes.fr/inserm-00857892

G. Mignot, E. Ullrich, M. Bonmort, C. Menard, and L. Apetoh, The Critical Role of IL-15 in the Antitumor Effects Mediated by the Combination Therapy Imatinib and IL-2, The Journal of Immunology, vol.180, issue.10, pp.6477-6483, 2008.
DOI : 10.4049/jimmunol.180.10.6477

URL : https://hal.archives-ouvertes.fr/hal-00364426

F. Ghiringhelli, C. Menard, P. Puig, S. Ladoire, and S. Roux, Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients, Cancer Immunology, Immunotherapy, vol.95, issue.5, pp.641-648, 2007.
DOI : 10.1007/s00262-006-0225-8

J. Vincent, G. Mignot, F. Chalmin, S. Ladoire, and M. Bruchard, 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity, Cancer Research, vol.70, issue.8, pp.3052-3061, 2010.
DOI : 10.1158/0008-5472.CAN-09-3690

L. Apetoh, C. Locher, F. Ghiringhelli, G. Kroemer, and L. Zitvogel, Harnessing dendritic cells in cancer, Seminars in Immunology, vol.23, issue.1, pp.42-49, 2011.
DOI : 10.1016/j.smim.2011.01.003

A. Tesniere, T. Panaretakis, O. Kepp, L. Apetoh, and F. Ghiringhelli, Molecular characteristics of immunogenic cancer cell death, Cell Death and Differentiation, vol.96, issue.1, pp.3-12, 2008.
DOI : 10.1016/S0092-8674(00)81683-9

M. Obeid, A. Tesniere, F. Ghiringhelli, G. Fimia, and L. Apetoh, Calreticulin exposure dictates the immunogenicity of cancer cell death, Nature Medicine, vol.279, issue.1, pp.54-61, 2007.
DOI : 10.1038/nm1523

URL : https://hal.archives-ouvertes.fr/inserm-00451702

L. Apetoh, F. Ghiringhelli, A. Tesniere, M. Obeid, and C. Ortiz, Toll-like receptor 4???dependent contribution of the immune system to anticancer chemotherapy and radiotherapy, Nature Medicine, vol.289, issue.9, pp.1050-1059, 2007.
DOI : 10.1038/nm1622

URL : https://hal.archives-ouvertes.fr/hal-00316924

F. Ghiringhelli, L. Apetoh, A. Tesniere, L. Aymeric, and Y. Ma, Activation of the NLRP3 inflammasome in dendritic cells induces IL-1?????dependent adaptive immunity against tumors, Nature Medicine, vol.7, issue.10, pp.1170-1178, 2009.
DOI : 10.1038/nm.2028

URL : https://hal.archives-ouvertes.fr/hal-00419823

V. Ryzhkov, V. Zeidlits, and K. Tikhonov, Use of protamine sulfate as a vasodilator in liver and spleen angiography], Vestn Rentgenol Radiol, pp.41-45, 1977.

J. Dresp, E. Schmid, and M. Bauchinger, The cytogenetic effect of bleomycin on human peripheral lymphocytes in vitro and in vivo, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol.56, issue.3, pp.341-353, 1978.
DOI : 10.1016/0027-5107(78)90203-8

W. Caspary, D. Lanzo, and C. Niziak, Effect of DNA on the production of reduced oxygen by bleomycin and iron, Biochemistry, vol.21, issue.2, pp.334-338, 1982.
DOI : 10.1021/bi00531a021

J. Hay, S. Shahzeidi, and G. Laurent, Mechanisms of bleomycin-induced lung damage, Archives of Toxicology, vol.88, issue.3, pp.81-94, 1991.
DOI : 10.1007/BF02034932

R. Meyer, M. Gospodarowicz, J. Connors, R. Pearcey, and W. Wells, ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma, New England Journal of Medicine, vol.366, issue.5, pp.399-408, 2012.
DOI : 10.1056/NEJMoa1111961

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932020

S. Williams, R. Birch, L. Einhorn, L. Irwin, and F. Greco, Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or Etoposide, New England Journal of Medicine, vol.316, issue.23, pp.1435-1440, 1987.
DOI : 10.1056/NEJM198706043162302

E. Bettelli, Y. Carrier, W. Gao, T. Korn, and T. Strom, Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells, Nature, vol.31, issue.7090, pp.235-238, 2006.
DOI : 10.1038/nature04753

F. Chalmin, S. Ladoire, G. Mignot, J. Vincent, and M. Bruchard, Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells, Journal of Clinical Investigation, vol.120, pp.457-471, 2010.
DOI : 10.1172/JCI40483DS1

URL : https://hal.archives-ouvertes.fr/inserm-00451697

F. Chalmin, G. Mignot, M. Bruchard, A. Chevriaux, and F. Vegran, Stat3 and Gfi-1 Transcription Factors Control Th17 Cell Immunosuppressive Activity via the Regulation of Ectonucleotidase Expression, Immunity, vol.36, issue.3, pp.362-373, 2012.
DOI : 10.1016/j.immuni.2011.12.019

URL : https://hal.archives-ouvertes.fr/inserm-00821485

R. Burger, J. Peisach, and S. Horwitz, Activated bleomycin. A transient complex of drug, iron, and oxygen that degrades DNA, J Biol Chem, vol.256, pp.11636-11644, 1981.

S. Wallach-dayan, G. Izbicki, P. Cohen, R. Gerstl-golan, and A. Fine, Bleomycin initiates apoptosis of lung epithelial cells by ROS but not by Fas/FasL pathway, AJP: Lung Cellular and Molecular Physiology, vol.290, issue.4, pp.790-796, 2006.
DOI : 10.1152/ajplung.00300.2004

A. Garg, D. Krysko, T. Verfaillie, A. Kaczmarek, and G. Ferreira, A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death, The EMBO Journal, vol.6, issue.5, pp.1062-1079, 2012.
DOI : 10.1038/emboj.2011.497

T. Panaretakis, O. Kepp, U. Brockmeier, A. Tesniere, and A. Bjorklund, Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death, The EMBO Journal, vol.65, issue.5, pp.578-590, 2009.
DOI : 10.1074/jbc.M512073200

T. Panaretakis, N. Joza, N. Modjtahedi, A. Tesniere, and I. Vitale, The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death, Cell Death and Differentiation, vol.21, issue.9, pp.1499-1509, 2008.
DOI : 10.1038/cdd.2008.67

M. Michaud, I. Martins, A. Sukkurwala, S. Adjemian, and Y. Ma, Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice, Science, vol.334, issue.6062, pp.1573-1577, 2011.
DOI : 10.1126/science.1208347

H. Tanaka, H. Matsushima, A. Nishibu, B. Clausen, and A. Takashima, Dual Therapeutic Efficacy of Vinblastine as a Unique Chemotherapeutic Agent Capable of Inducing Dendritic Cell Maturation, Cancer Research, vol.69, issue.17, pp.6987-6994, 2009.
DOI : 10.1158/0008-5472.CAN-09-1106

E. Suzuki, V. Kapoor, A. Jassar, L. Kaiser, and S. Albelda, Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity, Clinical Cancer Research, vol.11, issue.18, pp.6713-6721, 2005.
DOI : 10.1158/1078-0432.CCR-05-0883

A. Thornton, E. Donovan, C. Piccirillo, and E. Shevach, Cutting Edge: IL-2 Is Critically Required for the In Vitro Activation of CD4+CD25+ T Cell Suppressor Function, The Journal of Immunology, vol.172, issue.11, pp.6519-6523, 2004.
DOI : 10.4049/jimmunol.172.11.6519

L. Melencio, R. Mckallip, H. Guan, R. Ramakrishnan, and R. Jain, Role of CD4+CD25+ T regulatory cells in IL-2-induced vascular leak, International Immunology, vol.18, issue.10, pp.1461-1471, 2006.
DOI : 10.1093/intimm/dxl079

C. Thornton, J. Upham, M. Wikstrom, B. Holt, and G. White, Functional Maturation of CD4+CD25+CTLA4+CD45RA+ T Regulatory Cells in Human Neonatal T Cell Responses to Environmental Antigens/Allergens, The Journal of Immunology, vol.173, issue.5, pp.3084-3092, 2004.
DOI : 10.4049/jimmunol.173.5.3084

S. Huber, C. Schramm, H. Lehr, A. Mann, and S. Schmitt, Cutting Edge: TGF-?? Signaling Is Required for the In Vivo Expansion and Immunosuppressive Capacity of Regulatory CD4+CD25+ T Cells, The Journal of Immunology, vol.173, issue.11, pp.6526-6531, 2004.
DOI : 10.4049/jimmunol.173.11.6526

F. Ghiringhelli, P. Puig, S. Roux, A. Parcellier, and E. Schmitt, regulatory T cell proliferation, The Journal of Experimental Medicine, vol.71, issue.7, pp.919-929, 2005.
DOI : 10.1084/jem.191.7.1187

URL : https://hal.archives-ouvertes.fr/inserm-00857882

A. Tesniere, F. Schlemmer, V. Boige, O. Kepp, and I. Martins, Immunogenic death of colon cancer cells treated with oxaliplatin, Oncogene, vol.177, issue.4, pp.482-491, 2010.
DOI : 10.1172/JCI35180

M. Bruchard, G. Mignot, V. Derangere, F. Chalmin, and A. Chevriaux, Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth, Nature Medicine, vol.179, issue.1, 2012.
DOI : 10.1016/j.bios.2008.06.030

URL : https://hal.archives-ouvertes.fr/hal-00919371

L. Menger, E. Vacchelli, S. Adjemian, I. Martins, and Y. Ma, Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death, Science Translational Medicine, vol.4, issue.143, pp.143-199, 2012.
DOI : 10.1126/scitranslmed.3003807

S. Sakaguchi, Regulatory T Cells, Cell, vol.101, issue.5, pp.455-458, 2000.
DOI : 10.1016/S0092-8674(00)80856-9

URL : https://hal.archives-ouvertes.fr/hal-01358192

E. Shevach, CD4+ CD25+ suppressor T cells: more questions than answers, Nat Rev Immunol, vol.2, pp.389-400, 2002.

H. Nishikawa and S. Sakaguchi, Regulatory T cells in tumor immunity, International Journal of Cancer, vol.27, pp.759-767, 2010.
DOI : 10.1002/ijc.25429

E. Breen, S. Shull, S. Burne, M. Absher, and J. Kelley, mRNA in Rat Lung Fibroblasts, American Journal of Respiratory Cell and Molecular Biology, vol.6, issue.2, pp.146-152, 1992.
DOI : 10.1165/ajrcmb/6.2.146

H. Li, B. He, C. Que, and B. Weng, Expression of TGF-beta 1, PDGF and IGF- 1 mRNA in lung of bleomycin-A5-induced pulmonary fibrosis in rats, Chin Med J (Engl), vol.109, pp.533-536, 1996.

J. Gauldie, M. Kolb, K. Ask, G. Martin, and P. Bonniaud, Smad3 Signaling Involved in Pulmonary Fibrosis and Emphysema, Proceedings of the American Thoracic Society, vol.3, issue.8, pp.696-702, 2006.
DOI : 10.1513/pats.200605-125SF

N. Khalil and A. Greenberg, The role of TGF-beta in pulmonary fibrosis, Ciba Found Symp, vol.157, pp.194-207, 1991.

A. Rech and R. Vonderheide, Clinical Use of Anti-CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells, Annals of the New York Academy of Sciences, vol.55, issue.1, pp.99-106, 2009.
DOI : 10.1111/j.1749-6632.2009.04939.x

I. Calone and S. Souchelnytskyi, Inhibition of TGFbeta signaling and its implications in anticancer treatments, Exp Oncol, vol.34, pp.9-16, 2012.